Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome

Molecular and Cellular Endocrinology

Volumn 335, Issue 2, 2011, Pages 116-125

  Scotti, Leopoldina ^a   Irusta, Griselda ^a   Abramovich, Dalhia ^a,b   Tesone, Marta ^a,b   Parborell, Fernanda ^a  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiogenesis; GnRH I agonist; Luteolysis; OHSS; Ovary

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CHORIONIC GONADOTROPIN; CYCLINE; ESTRADIOL; LEUPRORELIN; PROGESTERONE; SERIC GONADOTROPIN; STEROIDOGENIC ACUTE REGULATORY PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS LUTEUM; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; GONADOTROPIN BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; LUTEAL CELL; NONHUMAN; OVARY DEVELOPMENT; OVARY HYPERSTIMULATION; PERITONEAL FLUID LEVEL; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; STEROIDOGENESIS; VASCULAR ENDOTHELIUM; VASCULAR STABILITY;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; APOPTOSIS; BLOOD VESSELS; CELL PROLIFERATION; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CORPUS LUTEUM; FEMALE; FERTILITY AGENTS, FEMALE; GONADAL STEROID HORMONES; GONADOTROPINS, EQUINE; LEUPROLIDE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; PHOSPHOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TIE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79951770237     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2011.01.002     Document Type: Article

References (70)

1. Aboulghar M.A., Mansour R.T. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum. Reprod. Update 2003, 9(3):275-289.
2. Abramovich D., Rodriguez C.A., Hernandez F., Tesone M., Parborell F. Spatiotemporal analysis of the protein expression of angiogenic factors and their related receptors during folliculogenesis in rats with and without hormonal treatment. Reproduction 2009, 137(2):309-320.
3. Andreu C., Parborell F., Vanzulli S., Chemes H., Tesone M. Regulation of follicular luteinization by a gonadotropin-releasing hormone agonist: relationship between steroidogenesis and apoptosis. Mol. Reprod. Dev. 1998, 51(3):287-294.
4. Budev M.M., Arroliga A.C., Falcone T. Ovarian hyperstimulation syndrome. Crit. Care Med. 2005, 33(10 Suppl.):S301-S306.
5. Challier J.C., Kacemi A., Olive G. Mixed culture of pericytes and endothelial cells from fetal microvessels of the human placenta. Cell Mol. Biol. (Noisy.-le-Grand) 1995, 41(2):233-241.
6. Chen C.D., Wu M.Y., Chen H.F., Chen S.U., Ho H.N., Yang Y.S. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil. Steril. 1999, 72(2):286-292.
7. D'Herde K., De Pestel G., Roels F. In situ end labeling of fragmented DNA in induced ovarian atresia. Biochem. Cell Biol. 1994, 72(11-12):573-579.
8. Dal Prato L., Borini A. Use of antagonists in ovarian stimulation protocols. Reprod. Biomed. Online 2005, 10(3):330-338.
9. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87(7):1161-1169.
10. Delvigne A., Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update 2002, 8(6):559-577.
11. Fauser B.C., de Jong D., Olivennes F., Wramsby H., Tay C., Itskovitz-Eldor J., van Hooren H.G. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab. 2002, 87(2):709-715.
12. Fraser H.M., Lunn S.F., Harrison D.J., Kerr J.B. Luteal regression in the primate: different forms of cell death during naturaland gonadotropin-releasing hormone antagonist or prostaglandin analogue-induced luteolysis. Biol. Reprod. 1999, 61(6):1468-1479.
13. Geva E., Jaffe R.B. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil. Steril. 2000, 74(3):429-438.
14. Giampietro F., Sancilio S., Tiboni G.M., Rana R.A., Di Pietro R. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist. Fertil. Steril. 2006, 85(2):412-419.
15. Golan A., Ron-El R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. 1989, 44(6):430-440.
16. Gomez R., Simon C., Remohi J., Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002, 143(11):4339-4348.
17. Goto T., Endo T., Henmi H., Kitajima Y., Kiya T., Nishikawa A., Manase K., Sato H., Kudo R. Gonadotropin-releasing hormone agonist has the ability to induce increased matrix metalloproteinase (MMP)-2 and membrane type 1-MMP expression in corpora lutea, and structural luteolysis in rats. J. Endocrinol. 1999, 161(3):393-402.
18. Harwood J.P., Clayton R.N., Chen T.T., Knox G., Catt K.J. Ovarian gonadotropin-releasing hormone receptors. II. Regulation and effects on ovarian development. Endocrinology 1980, 107(2):414-421.
19. Hayashi K.G., Acosta T.J., Tetsuka M., Berisha B., Matsui M., Schams D., Ohtani M., Miyamoto A. Involvement of angiopoietin-tie system in bovine follicular development and atresia: messenger RNA expression in theca interna and effect on steroid secretion. Biol. Reprod. 2003, 69(6):2078-2084.
20. Hazum E., Nimrod A. Photoaffinity-labeling and fluorescence-distribution studies of gonadotropin-releasing hormone receptors in ovarian granulosa cells. Proc. Natl. Acad. Sci. U.S.A. 1982, 79(6):1747-1750.
21. Hazzard T.M., Christenson L.K., Stouffer R.L. Changes in expression of vascular endothelial growth factor and angiopoietin-1 and -2 in the macaque corpus luteum during the menstrual cycle. Mol. Hum. Reprod. 2000, 6(11):993-998.
22. Hazzard T.M., Molskness T.A., Chaffin C.L., Stouffer R.L. Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval. Mol. Hum. Reprod. 1999, 5(12):1115-1121.
23. Hirschi K.K., D'Amore P.A. Pericytes in the microvasculature. Cardiovasc. Res. 1996, 32(4):687-698.
24. 2+ mobilization and steroidogenesis of human granulosa cells. Endocr. J. 1998, 45(2):175-182.
25. Hsueh A.J., Schaeffer J.M. Gonadotropin-releasing hormone as a paracrine hormone and neurotransmitter in extra-pituitary sites. J. Steroid Biochem. 1985, 23(5B):757-764.
26. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod. Biomed. Online 2009, 18(5):630-634.
27. Irusta G., Parborell F., Peluffo M., Manna P.R., Gonzalez-Calvar S.I., Calandra R., Stocco D.M., Tesone M. Steroidogenic acute regulatory protein in ovarian follicles of gonadotropin-stimulated rats is regulated by a gonadotropin-releasing hormone agonist. Biol. Reprod. 2003, 68(5):1577-1583.
28. Irusta G., Parborell F., Tesone M. Inhibition of cytochrome P-450 C17 enzyme by a GnRH agonist in ovarian follicles from gonadotropin-stimulated rats. Am. J. Physiol. Endocrinol. Metab. 2007, 292(5):E1456-E1464.
29. Jain R.K., Booth M.F. What brings pericytes to tumor vessels?. J. Clin. Invest. 2003, 112(8):1134-1136.
30. Kang S.K., Tai C.J., Nathwani P.S., Leung P.C. Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells. Endocrinology 2001, 142(1):182-192.
31. Kitajima Y., Endo T., Nagasawa K., Manase K., Honnma H., Baba T., Hayashi T., Chiba H., Sawada N., Saito H. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006, 147(2):694-699.
32. Kitajima Y., Endo T., Manase K., Nishikawa A., Shibuya M., Kudo R. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil. Steril. 2004, 81(Suppl. 1):842-849.
33. Kogo H., Fujimoto T., Mori T. Evidence for gonadotropin-releasing hormone receptor mRNA expression by estrogen in rat granulosa cells. Cell Tissue Res. 1999, 297(3):459-465.
34. Krasnow J.S., Berga S.L., Guzick D.S., Zeleznik A.J., Yeo K.T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil. Steril. 1996, 65(3):552-555.
35. Lee A., Christenson L.K., Stouffer R.L., Burry K.A., Patton P.E. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil. Steril. 1997, 68(2):305-311.
36. Levin E.R., Rosen G.F., Cassidenti D.L., Yee B., Meldrum D., Wisot A., Pedram A. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J. Clin. Invest. 1998, 102(11):1978-1985.
37. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277(5322):55-60.
38. McCracken J.A., Custer E.E., Lamsa J.C. Luteolysis: a neuroendocrine-mediated event. Physiol. Rev. 1999, 79(2):263-323.
39. Muttukrishna S., Fowler P.A., George L., Groome N.P., Knight P.G. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J. Clin. Endocrinol. Metab. 1996, 81(9):3328-3334.
40. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil. Steril. 1992, 58(2):249-261.
41. Nevo O., Eldar-Geva T., Kol S., Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil. Steril. 2003, 79(5):1123-1128.
42. Ozcakir H.T., Giray S.G., Ozbilgin M.K., Uyar Y., Lacin S., Caglar H. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary. Acta Obstet. Gynecol. Scand. 2005, 84(9):887-893.
43. Parborell F., Dain L., Tesone M. Gonadotropin-releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis. Mol. Reprod. Dev. 2001, 60(2):241-247.
44. Parborell F., Irusta G., Rodriguez C.A., Tesone M. Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs. Mol. Reprod. Dev. 2008, 75(4):623-631.
45. Parborell F., Irusta G., Vitale A.M., Gonzalez O., Pecci A., Tesone M. GnRH antagonist antide inhibits apoptosis of preovulatory follicle cells in rat ovary. Biol. Reprod. 2005, 72:659-666.
46. Parborell F., Pecci A., Gonzalez O., Vitale A., Tesone M. Effects of a gonadotropin-releasing hormone agonist on rat ovarian follicle apoptosis: regulation by EGF and the expression of Bcl-2-related genes. Biol. Reprod. 2002, 67:481-486.
47. Ragni G., Vegetti W., Riccaboni A., Engl B., Brigante C., Crosignani P.G. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum. Reprod. 2005, 20(9):2421-2425.
48. Redmer D.A., Doraiswamy V., Bortnem B.J., Fisher K., Jablonka-Shariff A., Grazul-Bilska A.T., Reynolds L.P. Evidence for a role of capillary pericytes in vascular growth of the developing ovine corpus luteum. Biol. Reprod. 2001, 65(3):879-889.
49. Reynolds L.P., Grazul-Bilska A.T., Redmer D.A. Angiogenesis in the corpus luteum. Endocrine 2000, 12(1):1-9.
50. Rizk B., Aboulghar M., Smitz J., Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum. Reprod. Update 1997, 3(3):255-266.
51. Sadrkhanloo R., Hofeditz C., Erickson G.F. Evidence for widespread atresia in the hypophysectomized estrogen-treated rat. Endocrinology 1987, 120(1):146-155.
52. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219(4587):983-985.
53. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376(6535):62-66.
54. Sifer C., Blanc-Layrac G., Bringuier A.F., Porcher R., Madelenat P., Feldmann G., Benifla J.L. Effects of a gonadotropin-releasing hormone agonist and follicle stimulating hormone on the incidence of apoptosis in human luteinized granulosa cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003, 110(1):43-48.
55. Sridaran R., Philip G.H., Li H., Culty M., Liu Z., Stocco D.M., Papadopoulos V. GnRH agonist treatment decreases progesterone synthesis, luteal peripheral benzodiazepine receptor mRNA, ligand binding and steroidogenic acute regulatory protein expression during pregnancy. J. Mol. Endocrinol. 1999, 22(1):45-54.
56. Sugino N., Suzuki T., Sakata A., Miwa I., Asada H., Taketani T., Yamagata Y., Tamura H. Angiogenesis in the human corpus luteum: changes in expression of angiopoietins in the corpus luteum throughout the menstrual cycle and in early pregnancy. J. Clin. Endocrinol. Metab. 2005, 90(11):6141-6148.
57. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87(7):1171-1180.
58. Takekida S., Matsuo H., Maruo T. GnRH agonist action on granulosa cells at varying follicular stages. Mol. Cell. Endocrinol. 2003, 202(1-2):155-164.
59. Tanaka J., Acosta T.J., Berisha B., Tetsuka M., Matsui M., Kobayashi S., Schams D., Miyamoto A. Relative changes in mRNA expression of angiopoietins and receptors tie in bovine corpus luteum during estrous cycle and prostaglandin F2alpha-induced luteolysis: a possible mechanism for the initiation of luteal regression. J. Reprod. Dev. 2004, 50(6):619-626.
60. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., Glazer N., Holash J., McDonald D.M., Yancopoulos G.D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 2000, 6(4):460-463.
61. Tong X.M., Zhang S.Y., Song T., Xu W.H., Lin X.N., Shu J., Liu L. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin. Med. J. (Engl.) 2008, 121(23):2434-2439.
62. Uemura T., Namiki T., Kimura A., Yanagisawa T., Minaguchi H. Direct effects of gonadotropin-releasing hormone on the ovary in rats and humans. Horm. Res. 1994, 41(Suppl. 1):7-13.
63. Ujioka T., Matsuura K., Kawano T., Okamura H. Role of progesterone in capillary permeability in hyperstimulated rats. Hum. Reprod. 1997, 12(8):1629-1634.
64. Vitale A.M., Abramovich D., Peluffo M.C., Meresman G., Tesone M. Effect of gonadotropin-releasing hormone agonist and antagonist on proliferation and apoptosis of human luteinized granulosa cells. Fertil. Steril. 2006, 85(4):1064-1067.
65. Whitelaw P.F., Eidne K.A., Sellar R., Smyth C.D., Hillier S.G. Gonadotropin-releasing hormone receptor messenger ribonucleic acid expression in rat ovary. Endocrinology 1995, 136(1):172-179.
66. Woodruff T.K., D'Agostino J., Schwartz N.B., Mayo K.E. Dynamic changes in inhibin messenger RNAs in rat ovarian follicles during the reproductive cycle. Science 1988, 239(4845):1296-1299.
67. Wulff C., Wiegand S.J., Saunders P.T., Scobie G.A., Fraser H.M. Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology 2001, 142(7):3244-3254.
68. Wulff C., Wilson H., Largue P., Duncan W.C., Armstrong D.G., Fraser H.M. Angiogenesis in the human corpus luteum: localization and changes in angiopoietins, Tie-2, and vascular endothelial growth factor messenger ribonucleic acid. J. Clin. Endocrinol. Metab. 2000, 85(11):4302-4309.
69. Yang H., Bhat G.K., Wadley R., Wright K.L., Chung B.M., Whittaker J.A., Dharmarajan A.M., Sridaran R. Gonadotropin-releasing hormone-agonist inhibits synthesis of nitric oxide and steroidogenesis by luteal cells in the pregnant rat. Biol. Reprod. 2003, 68(6):2222-2231.
70. Zhao S., Saito H., Wang X., Saito T., Kaneko T., Hiroi M. Effects of gonadotropin-releasing hormone agonist on the incidence of apoptosis in porcine and human granulosa cells. Gynecol. Obstet. Invest. 2000, 49(1):52-56.